Createrna Science & Technology

Createrna Science & Technology is a clinical-stage biopharmaceutical company headquartered in Zhuhai, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on high-prevalence chronic conditions, particularly in the fields of metabolic, cardiovascular, and autoimmune diseases. Its lead candidate, CK0801, is a highly potent URAT1 inhibitor currently in Phase 3 clinical trials for the treatment of gout and hyperuricemia. Createrna maintains a robust internal R&D engine with additional programs targeting SGLT2, JAK1, and TYK2 pathways. The company aims to provide affordable and effective therapeutic solutions for patients globally through its integrated drug discovery platform.